Abstract
Inflammatory bowel diseases represent a heterogeneous group of chronic diseases occurring as a result of disruption of interaction processes between the mucosal immune system and the colon commensal ecosystem. The key role of the intestinal microbiota in the pathogenesis of ulcerative colitis, as well as its definition as a deterministic factor influencing the status of immune activation and the severity of the disease, is confirmed in many studies. Accumulating evidence suggests that non-antibacterial drugs are able to modulate the composition of the intestinal microbiota, which in turn may determine the effectiveness of pharmacological therapy and the clinical outcome. The article presents a review of literature on the impact of drugs used in the treatment of ulcerative colitis on the bacterial community of the colon.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
